Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous 
cell carcinoma

Martin, D.; Roedel, F.; Hehlgans, S.; Looso, M.; Ziegler, P. K.; Fleischmann, M.; Diefenhardt, M.; Fries, L.; Kalinauskaite, G.; Tinhofer, I.; Zips, D.; Gani, C.; Roedel, C.; Fokas, E.

doi:10.1038/s41698-024-00585-y

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma

MPS-Authors

/persons/resource/persons224384

Looso, M.
Bioinformatics, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Martin, D., Roedel, F., Hehlgans, S., Looso, M., Ziegler, P. K., Fleischmann, M., Diefenhardt, M., Fries, L., Kalinauskaite, G., Tinhofer, I., Zips, D., Gani, C., Roedel, C., & Fokas, E. (2024). Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma. NPJ PRECISION ONCOLOGY, 8(1):. doi:10.1038/s41698-024-00585-y.

引用: https://hdl.handle.net/21.11116/0000-000F-51A3-D

要旨

Anal squamous cell carcinoma (ASCC) is associated with immunosuppression and infection with human papillomavirus (HPV). Response to standard chemoradiotherapy (CRT) varies considerably. A comprehensive molecular characterization of CRT resistance is lacking, and little is known about the interplay between tumor immune contexture, host immunity, and immunosuppressive and/or immune activating effects of CRT. Patients with localized ASCC, treated with CRT at three different sites of the German Cancer Consortium (DKTK) were included. Patient cohorts for molecular analysis included baseline formalin fixed paraffin embedded biopsies for immunohistochemistry (n = 130), baseline RNA sequencing (n = 98), peripheral blood immune profiling (n = 47), and serum cytokine measurement (n = 35). Gene set enrichment analysis showed that pathways for IFN gamma, IFN alpha, inflammatory response, TNF alpha signaling via NF-kappa B, and EMT were significantly enriched in poor responders (all p < 0.001). Expression of interferon-induced transmembrane protein 1 (IFITM1), both on mRNA and protein levels, was associated with reduced Freedom from locoregional failure (FFLF, p = 0.037) and freedom from distant metastasis (FFDM, p = 0.014). An increase of PD-L1 expression on CD4+ T-cells (p < 0.001) and an increase in HLA-DR expression on T-cells (p < 0.001) was observed in the peripheral blood after CRT. Elevated levels of regulatory T-cells and CXCL2 were associated with reduced FFLF (p = 0.0044 and p = 0.004, respectively). Inflammatory pathways in tissue in line with elevated levels of regulatory T-cells and CXCL2 in peripheral blood are associated with resistance to CRT. To counteract this resistance mechanism, the RADIANCE randomized phase-2 trial currently tests the addition of the immune checkpoint inhibitor durvalumab to standard CRT in locally advanced ASCC.